Literature DB >> 10815690

Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.

P M Marcus1, R B Hayes, P Vineis, M Garcia-Closas, N E Caporaso, H Autrup, R A Branch, J Brockmöller, T Ishizaki, A E Karakaya, J M Ladero, S Mommsen, H Okkels, M Romkes, I Roots, N Rothman.   

Abstract

Tobacco use is an established cause of bladder cancer. The ability to detoxify aromatic amines, which are present in tobacco and are potent bladder carcinogens, is compromised in persons with the N-acetyltransferase 2 slow acetylation polymorphism. The relationship of cigarette smoking with bladder cancer risk therefore has been hypothesized to be stronger among slow acetylators. The few studies to formally explore such a possibility have produced inconsistent results, however. To assess this potential gene-environment interaction in as many bladder cancer studies as possible and to summarize results, we conducted a meta-analysis using data from 16 bladder cancer studies conducted in the general population (n = 1999 cases), Most had been conducted in European countries. Because control subjects were unavailable for a number of these studies, we used a case-series design, which can be used to assess multiplicative gene-environment interaction without inclusion of control subjects. A case-series interaction odds ratio (OR) > 1.0 indicates that the relationship of cigarette smoking and bladder cancer risk is stronger among slow acetylators as compared with rapid acetylators. We observed an interaction between smoking and N-acetyltransferase 2 slow acetylation (OR, 1.3; 95% confidence interval, 1.0-1.6) that was somewhat stronger when analyses were restricted to studies conducted in Europe (OR, 1.5; confidence interval, 1.1-1.9), a pooling that included nearly 80% of the collected data. Using the predominantly male European study population and assuming a 2.5-fold elevation in bladder cancer risk from smoking, we estimated that the population attributable risk percent was 35% for slow acetylators who had ever smoked and 13% for rapid acetylators who had ever smoked. These results suggest that the relationship of smoking and bladder cancer is stronger among slow acetylators than among rapid acetylators.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10815690

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  22 in total

Review 1.  The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review.

Authors:  Maurice P A Zeegers; Eliane Kellen; Frank Buntinx; Piet A van den Brandt
Journal:  World J Urol       Date:  2003-12-17       Impact factor: 4.226

Review 2.  A systematic review evaluating the methodological aspects of meta-analyses of genetic association studies in cancer research.

Authors:  Stefania Boccia; Emma De Feo; Paola Gallì; Francesco Gianfagna; Rosarita Amore; Gualtiero Ricciardi
Journal:  Eur J Epidemiol       Date:  2010-09-10       Impact factor: 8.082

3.  NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.

Authors:  Montserrat García-Closas; Núria Malats; Debra Silverman; Mustafa Dosemeci; Manolis Kogevinas; David W Hein; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Gemma Castaño-Vinyals; Meredith Yeager; Robert Welch; Stephen Chanock; Nilanjan Chatterjee; Sholom Wacholder; Claudine Samanic; Montserrat Torà; Francisco Fernández; Francisco X Real; Nathaniel Rothman
Journal:  Lancet       Date:  2005 Aug 20-26       Impact factor: 79.321

Review 4.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

Review 5.  Understanding the gender disparity in bladder cancer risk: the impact of sex hormones and liver on bladder susceptibility to carcinogens.

Authors:  Yuesheng Zhang
Journal:  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev       Date:  2013       Impact factor: 3.781

6.  Association between co-inhibitory molecule gene tagging single nucleotide polymorphisms and the risk of colorectal cancer in Chinese.

Authors:  Jie Ge; Lin Zhu; Junde Zhou; Guangxiao Li; Ye Li; Shuying Li; Zhiwei Wu; Jiesheng Rong; Huiping Yuan; Yanhong Liu; Qiang Chi; Daxun Piao; Yashuang Zhao; Binbin Cui
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-22       Impact factor: 4.553

7.  The case-only independence assumption: associations between genetic polymorphisms and smoking among controls in two population-based studies.

Authors:  M Elizabeth Hodgson; Andrew F Olshan; Kari E North; Charles L Poole; Donglin Zeng; Chiu-Kit Tse; Tope O Keku; Joseph Galanko; Robert Sandler; Robert C Millikan
Journal:  Int J Mol Epidemiol Genet       Date:  2012-11-15

8.  Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers.

Authors:  Sam S Oh; Shen-Chih Chang; Lin Cai; Carlos Cordon-Cardo; Bao-Guo Ding; Sander Greenland; Na He; Qingwu Jiang; Leeka Kheifets; Anh Le; Yuan-Chin Amy Lee; Simin Liu; Ming-Lan Lu; Jenny T Mao; Hal Morgenstern; Li-Na Mu; Allan Pantuck; Jeanette C Papp; Sungshim Lani Park; Jian Yu Rao; Victor E Reuter; Donald P Tashkin; Hua Wang; Nai-Chieh Y You; Shun-Zhang Yu; Jin-Kou Zhao; Arie Belldegrun; Zuo-Feng Zhang
Journal:  Int J Cancer       Date:  2010-11-01       Impact factor: 7.396

9.  Effect of NAT2 gene polymorphism on bladder cancer risk in Slovak population.

Authors:  Lucia Klimčáková; Viera Habalová; Monika Sivoňová; Vincent Nagy; Ján Šalagovič; Jozef Židzik
Journal:  Mol Biol Rep       Date:  2010-06-22       Impact factor: 2.316

Review 10.  The health economics of bladder cancer: a comprehensive review of the published literature.

Authors:  Marc F Botteman; Chris L Pashos; Alberto Redaelli; Benjamin Laskin; Robert Hauser
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.